E-LIB Suche - Ergebnisse für: Burris III, Howard A.

1

Durvalumab or placebo plus gemcitabine and cisplatin in par..:

Oh, Do-Youn ; He, Aiwu Ruth ; Bouattour, Mohamed...
The Lancet Gastroenterology & Hepatology. , 2024

Link: https://doi.org/10.1016/..

2

Durvalumab plus gemcitabine and cisplatin in advanced bilia..:

Burris III, Howard A ; Okusaka, Takuji ; Vogel, Arndt...
The Lancet Oncology. 25 (2024) 5 - p. 626-635 , 2024

Link: https://doi.org/10.1016/..

3

The evolving landscape of tissue‐agnostic therapies in prec..:

Subbiah, Vivek ; Gouda, Mohamed A. ; Ryll, Bettina..
CA: A Cancer Journal for Clinicians. , 2024

Link: https://doi.org/10.3322/..

4

XENERA-1: a randomised double-blind Phase II trial of xentu..:

Schmid, Peter ; Cortes, Javier ; Joaquim, Ana...
Breast Cancer Research. 25 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

5

Safety, tolerability, and pharmacokinetics of Aurora kinase..:

Johnson, Melissa L. ; Wang, Judy S. ; Falchook, Gerald...
British Journal of Cancer. 128 (2023) 10 - p. 1906-1915 , 2023

Link: https://doi.org/10.1038/..

6

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topote..:

Johnson, Melissa L ; Patel, Manish R ; Aljumaily, Raid...
The Oncologist. 28 (2023) 7 - p. 640-e559 , 2023

Link: https://doi.org/10.1093/..

7

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibitio..:

Gordon, Leo I. ; Karmali, Reem ; Kaplan, Jason B....
Oncotarget. 14 (2023) 1 - p. 57-70 , 2023

Link: https://doi.org/10.18632..

8

A randomized phase II study of metronomic cyclophosphamide ..:

Mayer, Erica L. ; Tayob, Nabihah ; Ren, Siyang...
Breast Cancer Research and Treatment. , 2023

Link: https://doi.org/10.1007/..

9

Revolutionizing cancer drug development: Harnessing the pot..:

Subbiah, Vivek ; Burris III, Howard A. ; Kurzrock, Razelle
Cancer. 130 (2023) 2 - p. 186-200 , 2023

Link: https://doi.org/10.1002/..

10

54. Concordance of blood and tissue TMB from real-world NGS..:

Sturgill, Emma ; Misch, Amanda ; Jones, Carissa...
Cancer Genetics. 260-261 (2022) - p. 18 , 2022

Link: https://doi.org/10.1016/..

11

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 i..:

Kim, Tae Won ; Burris III, Howard A. ; de Miguel Luken, Maria J....
Clinical Cancer Research. 28 (2022) 16 - p. 3452-3463 , 2022

Link: https://doi.org/10.1158/..

12

Discordance in Tumor Mutation Burden from Blood and Tissue ..:

Sturgill, Emma G ; Misch, Amanda ; Jones, Carissa C...
The Oncologist. 27 (2022) 3 - p. 175-182 , 2022

Link: https://doi.org/10.1093/..

13

Atezolizumab Treatment of Tumors with High Tumor Mutational..:

Friedman, Claire F. ; Hainsworth, John D. ; Kurzrock, Razelle...
Cancer Discovery. 12 (2022) 3 - p. 654-669 , 2022

Link: https://doi.org/10.1158/..

14

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurren..:

Mellinghoff, Ingo K. ; Penas-Prado, Marta ; Peters, Katherine B....
Clinical Cancer Research. 27 (2021) 16 - p. 4491-4499 , 2021

Link: https://doi.org/10.1158/..

15

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) ..:

Voss, Martin H. ; Gordon, Michael S. ; Mita, Monica...
British Journal of Cancer. 123 (2020) 11 - p. 1590-1598 , 2020

Link: https://doi.org/10.1038/..